For example, an alternative biomolecular target in prostate cancer is PSMA, prompting the development of several radiolabeled PSMA inhibitors dynamically entering the field of nuclear medicine as novel diagnostic and therapeutic tools [102]. This evidence concerns the gene FOLH1 and prostate cancer.